Operator

Good day, and thank you for standing by. Welcome to the Kura Oncology Discussion of FTI Clinical Data at the ESMO 2025 Congress. [Operator Instructions] Please be advised that today’s conference is being recorded. I would now like to turn the conference over to your first speaker to Troy Wilson, President and CEO of Kura Oncology. Please go ahead.

Troy Wilson
Chairman, CEO & President

Thank you, Dulum. Good morning, good afternoon, good evening, everyone. As Dulum mentioned, I’m Troy Wilson, Kura Oncology’s President and Chief Executive Officer, and it’s a pleasure to have us here with you today to review our farnesyl transferase program and in particular, our clinical updates from ESMO in 2025. This is the second in a 2-part series. The first part was a discussion of the preclinical data and rationale which was presented on September 16 last month. For those interested, that webcast and those slides are available on the Kura Oncology website. If we could please go to the next slide.

In today’s presentation, we’re going to be making certain forward-looking statements. I would refer you either to our website or to the SEC’s website for more information about the risks of an investment in Kura Oncology. If we could